RenovoRx, Inc. (RNXT)

Market Cap	34.64M +5.3%
Revenue (ttm)	928,000
Net Income	-11.11M
EPS	-0.34
Shares Out	36.65M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	97,652
Open	1.0000
Previous Close	0.9992
Day's Range	0.9400 - 1.0000
52-Week Range	0.7006 - 1.4500
Beta	1.31
Analysts	Strong Buy
Price Target	8.00 (+746.47%)
Earnings Date	Mar 30, 2026

About RNXT

RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in the developing of targeted combination therapies to enhance therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer. RenovoRx, Inc. was founded in 2009 and is headquartered in Mountain View, California.

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Aug 26, 2021
• Employees: 10
• Stock Exchange: NASDAQ
• Ticker Symbol: RNXT
• Website: https://renovorx.com

Analyst Summary

According to 2 analysts, the average rating for RNXT stock is "Strong Buy." The 12-month stock price target is $8.0, which is an increase of 746.47% from the latest price.

Price Target

$8.0

(746.47% upside)

Analyst Consensus: Strong Buy